Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 3/20 | 0.31 |
| ▸ | RAB9A | P51151 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | OGA | O60502 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13161907 | 0.90 | RAB9A (0.37) | ALDH1A1GAAMAPK1NPC1RAB9A | |
| SCHEMBL13162281 | 0.86 | MAPT (0.37) | ALDH1A1GAAMAPK1NPC1RAB9A | |
| SCHEMBL13270611 | 0.80 | AR (0.44) | ALDH1A1MAPK1NPC1RAB9AMAPT | |
| SCHEMBL13162279 | 0.78 | AR (0.47) | ALDH1A1MAPK1NPC1RAB9AMAPT | |
| SCHEMBL13638865 | 0.77 | LMNA (0.52) | ALDH1A1GAAMAPK1NPC1RAB9A | |
| SCHEMBL13161927 | 0.77 | NPC1 (0.36) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL13161918 | 0.76 | AR (0.31) | NPC1RAB9AAR | |
| SCHEMBL13162283 | 0.76 | LMNA (0.37) | ALDH1A1GAAMAPK1NPC1RAB9A | |
| SCHEMBL13162294 | 0.75 | ADK (0.35) | ALDH1A1GAAMAPK1RAB9AMAPT | |
| SCHEMBL13162783 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2206707-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | TRPV1, FGFR3, GPR17 | ALDH1A1 1659/4885GAA 4334/4885MAPK1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.